EU Approves First Universal HER2 Cancer Treatment

Patients with rare, aggressive cancers just gained a powerful new weapon in their fight for survival.

The European Union approved Enhertu as the first cancer treatment that works across multiple tumor types, as long as they share a specific marker called HER2. This marks a major shift in how doctors can treat cancer, focusing on what makes the tumor grow rather than where it started in the body.

Until now, targeted HER2 therapies were only available for breast, gastric, and lung cancers. Patients with other HER2-positive cancers like pancreatic, bladder, cervical, or ovarian tumors had limited options once standard treatments stopped working.

The approval covers adult patients with HER2-positive advanced solid tumors who have already tried other treatments. In clinical trials, the drug helped shrink tumors in about half of patients across different cancer types, with some seeing benefits lasting nearly two years.

Dr. Benedikt Westphalen from the University of Munich explained that HER2 overexpression is linked to aggressive disease and poor outcomes. Having a treatment option regardless of where the cancer originated opens new doors for patients who previously had nowhere to turn.

The approval was based on three clinical trials involving patients with various cancers. In one study of 111 patients with rare HER2-positive tumors, over 52% saw their tumors shrink significantly. Some patients with pancreatic, bladder, and other hard-to-treat cancers experienced responses lasting more than 21 months.

The Bright Side

This approval represents a fundamental change in cancer treatment philosophy. Instead of treating cancer based solely on its location, doctors can now target specific biological characteristics that fuel tumor growth.

The shift toward precision medicine means better biomarker testing and more personalized care. Patients with rare cancers who felt forgotten by medical research now have evidence that treatments are being developed with them in mind.

AstraZeneca and Daiichi Sankyo, who jointly developed the drug, already have additional applications under review in Europe. They're testing combinations and earlier treatment stages that could help even more patients.

For families facing diagnoses that once meant running out of options, this approval brings tangible hope and more time.